Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X:
“MSI-H/dMMR: the perfect storm for immunotherapy.
– High TMB, tons of neoantigens, and inflamed tumors. Long-term survivors, even cures.
– Up to 40% still fail.
Cure or collapse, the paradox of MSI-H/dMMR. The success story.
Metastatic Colorectal Cancer: Immunotherapy vs chemo. KEYNOTE-177 →↑ PFS, ORR ~45%, CR ~30%. CheckMate-8HW → ORR ~70%, 2-yr PFS ~72%.
Localized CRC: NICHE-2 → 95% MPR, 67% pCR, 3-yr DFS 100%.
ICI achieves durable survival and, in some cases, cure.
Title: Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Authors: Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taieb, Filippo Pietrantonio
More posts featuring Oscar Tahuahua.